TP53 and hematologic disorder: Previous findings by Drygin et al. [8] and by Hein et al. [11] showed that CX-5461 was most potent against cell lines derived from human hematological malignancies with wild-type p53 status, whereas median IC50 levels in those cell lines with mutated p53 were shown to be several-fold higher.